# Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Study · id `cardio:ct-nct05199090` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05199090](<https://clinicaltrials.gov/study/NCT05199090>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05199090

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 126 participants.

## Technical summary

Registry record NCT05199090. Randomized; double masking; primary purpose treatment. Start 2022-02-10 (actual); primary completion 2023-05-11 (actual). Results posted on 2024-05-31.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 126 participants (enrolled count; ClinicalTrials.gov record NCT05199090, source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)
- Started: 2022-02-10 (actual) (ClinicalTrials.gov record NCT05199090, source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)
- Primary completion: 2023-05-11 (actual) (ClinicalTrials.gov record NCT05199090, source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)
- Completion: 2023-05-11 (actual) (ClinicalTrials.gov record NCT05199090, source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)
- Results first posted: 2024-05-31 (ClinicalTrials.gov record NCT05199090, source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05199090, source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05199090-2024-10-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
- Condition: Obesity
- Intervention (Drug): MBL949
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: bd1134721102c16e1a68886896323c759541c7a71633ce794224c8b5a98174ae
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
